KV Pharmaceutical Company announced Monday that its reorganization plan is in effect, and it has emerged from bankruptcy.
Based in Bridgeton, the company filed for bankruptcy Aug. 4, 2012.
KV is primarily focused on women’s healthcare, but the company has had struggles in recent years.
That includes a failed lawsuit against the FDA, which refused to prevent competitors from selling a much lower cost version of Makena.
KV initially charged as much as $1,500 for a dose of Makena, which is meant to reduce the risk of premature births.